234 related articles for article (PubMed ID: 27213960)
1. Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMB-CHMICA.
Seywright A; Torrance HJ; Wylie FM; McKeown DA; Lowe DJ; Stevenson R
Clin Toxicol (Phila); 2016 Sep; 54(8):632-7. PubMed ID: 27213960
[TBL] [Abstract][Full Text] [Related]
2. Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study.
Hill SL; Najafi J; Dunn M; Acheampong P; Kamour A; Grundlingh J; Blain PG; Thomas SH
Clin Toxicol (Phila); 2016 Sep; 54(8):638-43. PubMed ID: 27251903
[TBL] [Abstract][Full Text] [Related]
3. Analytically Confirmed Intoxications Involving MDMB-CHMICA from the STRIDA Project.
Bäckberg M; Tworek L; Beck O; Helander A
J Med Toxicol; 2017 Mar; 13(1):52-60. PubMed ID: 27638057
[TBL] [Abstract][Full Text] [Related]
4. Fatal intoxication with synthetic cannabinoid MDMB-CHMICA.
Adamowicz P
Forensic Sci Int; 2016 Apr; 261():e5-10. PubMed ID: 26934903
[TBL] [Abstract][Full Text] [Related]
5. Phase I metabolism of the highly potent synthetic cannabinoid MDMB-CHMICA and detection in human urine samples.
Franz F; Angerer V; Moosmann B; Auwärter V
Drug Test Anal; 2017 May; 9(5):744-753. PubMed ID: 27504870
[TBL] [Abstract][Full Text] [Related]
6. Poisoning due to MDMB-CHMICA, a synthetic cannabinoid receptor agonist.
Meyyappan C; Ford L; Vale A
Clin Toxicol (Phila); 2017 Feb; 55(2):151-152. PubMed ID: 27635694
[No Abstract] [Full Text] [Related]
7. Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA.
Hermanns-Clausen M; Müller D; Kithinji J; Angerer V; Franz F; Eyer F; Neurath H; Liebetrau G; Auwärter V
Clin Toxicol (Phila); 2018 Jun; 56(6):404-411. PubMed ID: 29072524
[TBL] [Abstract][Full Text] [Related]
8. Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015.
Abouchedid R; Hudson S; Thurtle N; Yamamoto T; Ho JH; Bailey G; Wood M; Sadones N; Stove CP; Dines A; Archer JRH; Wood DM; Dargan PI
Clin Toxicol (Phila); 2017 Jun; 55(5):338-345. PubMed ID: 28421836
[TBL] [Abstract][Full Text] [Related]
9. Post-mortem distribution of the synthetic cannabinoid MDMB-CHMICA and its metabolites in a case of combined drug intoxication.
Gaunitz F; Lehmann S; Thomas A; Thevis M; Rothschild MA; Mercer-Chalmers-Bender K
Int J Legal Med; 2018 Nov; 132(6):1645-1657. PubMed ID: 30219927
[TBL] [Abstract][Full Text] [Related]
10. MDMB-CHMICA: Availability, Patterns of Use, and Toxicity Associated With This Novel Psychoactive Substance.
Haden M; Archer JR; Dargan PI; Wood DM
Subst Use Misuse; 2017 Jan; 52(2):223-232. PubMed ID: 27759479
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous detection of 93 synthetic cannabinoids by liquid chromatography-tandem mass spectrometry and retrospective application to real forensic samples.
Hess C; Murach J; Krueger L; Scharrenbroch L; Unger M; Madea B; Sydow K
Drug Test Anal; 2017 May; 9(5):721-733. PubMed ID: 27400642
[TBL] [Abstract][Full Text] [Related]
12. Acute intoxication of four individuals following use of the synthetic cannabinoid MAB-CHMINACA.
Adamowicz P; Gieroń J
Clin Toxicol (Phila); 2016 Sep; 54(8):650-4. PubMed ID: 27227269
[TBL] [Abstract][Full Text] [Related]
13. Sudden Cardiac Death Following Use of the Synthetic Cannabinoid MDMB-CHMICA.
Westin AA; Frost J; Brede WR; Gundersen PO; Einvik S; Aarset H; Slørdal L
J Anal Toxicol; 2016; 40(1):86-7. PubMed ID: 26353925
[No Abstract] [Full Text] [Related]
14. Chemical profiling of the synthetic cannabinoid MDMB-CHMICA: Identification, assessment, and stability study of synthesis-related impurities in seized and synthesized samples.
Münster-Müller S; Hansen S; Opatz T; Zimmermann R; Pütz M
Drug Test Anal; 2019 Aug; 11(8):1192-1206. PubMed ID: 31124282
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of the synthetic cannabinoid, 5F-MDMB-PICA, in male rats.
Krotulski AJ; Garibay N; Walther D; Walton SE; Mohr ALA; Logan BK; Baumann MH
Neuropharmacology; 2021 Nov; 199():108800. PubMed ID: 34547333
[TBL] [Abstract][Full Text] [Related]
16. In vitro Phase I metabolism of indazole carboxamide synthetic cannabinoid MDMB-CHMINACA via human liver microsome incubation and high-resolution mass spectrometry.
Presley BC; Logan BK; Jansen-Varnum SA
Drug Test Anal; 2019 Aug; 11(8):1264-1276. PubMed ID: 31108568
[TBL] [Abstract][Full Text] [Related]
17. A Novel Impurity-Profiling Workflow with the Combination of Flash-Chromatography, UHPLC-MS, and Multivariate Data Analysis for Highly Pure Drugs: A Study on the Synthetic Cannabinoid MDMB-CHMICA.
Münster-Müller S; Zimmermann R; Pütz M
Anal Chem; 2018 Sep; 90(17):10559-10567. PubMed ID: 30079731
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Synthetic Cannabinoid Metabolites in Human Blood in the Absence of Parent Compounds: A Stability Assessment.
Krotulski AJ; Bishop-Freeman SC; Mohr ALA; Logan BK
J Anal Toxicol; 2021 Feb; 45(1):60-68. PubMed ID: 32435808
[TBL] [Abstract][Full Text] [Related]
19. Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents?
Tebo C; Mazer-Amirshahi M; DeGeorge L; Gelfand B; Leak C; Tolliver S; Sauter D
Am J Emerg Med; 2019 Oct; 37(10):1846-1849. PubMed ID: 30595429
[TBL] [Abstract][Full Text] [Related]
20. The impact of the Psychoactive Substances Act 2016 on the online availability of MDMB-CHMICA.
Haden M; Wood DM; Dargan PI
QJM; 2017 Oct; 110(10):619-622. PubMed ID: 28339898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
